Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study.

IF 2.7 4区医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-09-03 DOI:10.1080/1750743X.2024.2382665

Leila Haghani, Chenyang Zhan, Hooman Yarmohammadi, Etay Ziv, Vlasios S Sotirchos, Debkumar Sarkar, Alexander N Shoushtari, Joseph P Erinjeri

{"title":"Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study.","authors":"Leila Haghani, Chenyang Zhan, Hooman Yarmohammadi, Etay Ziv, Vlasios S Sotirchos, Debkumar Sarkar, Alexander N Shoushtari, Joseph P Erinjeri","doi":"10.1080/1750743X.2024.2382665","DOIUrl":null,"url":null,"abstract":"Aim: To investigate how the sequence of checkpoint immunotherapy (CPI) and transarterial embolization (TAE) affects overall survival (OS) of patients with metastatic melanoma.Materials & methods: This retrospective cohort study included 65 patients with metastatic melanoma who underwent both TAE and CPI between September 2011 and January 2022.Results: Significantly higher OS was seen in patients who received CPI before and after embolization (22 months, 95% CI 14-NR, p < 0.001) compared with only before embolization (4.5 months 95% CI, 14-NR). ≤3 hepatic metastasis (p < 0.01), more TAE procedures (p < 0.001) and CPI sequence (before and after embolization) (p < 0.001) were independent predictors of survival.Conclusion: Metastatic melanoma patients who underwent TAE have longer survival when CPI was sequenced both before and after embolization.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"955-962"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485943/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2382665","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate how the sequence of checkpoint immunotherapy (CPI) and transarterial embolization (TAE) affects overall survival (OS) of patients with metastatic melanoma.Materials & methods: This retrospective cohort study included 65 patients with metastatic melanoma who underwent both TAE and CPI between September 2011 and January 2022.Results: Significantly higher OS was seen in patients who received CPI before and after embolization (22 months, 95% CI 14-NR, p < 0.001) compared with only before embolization (4.5 months 95% CI, 14-NR). ≤3 hepatic metastasis (p < 0.01), more TAE procedures (p < 0.001) and CPI sequence (before and after embolization) (p < 0.001) were independent predictors of survival.Conclusion: Metastatic melanoma patients who underwent TAE have longer survival when CPI was sequenced both before and after embolization.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

转移性黑色素瘤患者的免疫疗法和经动脉栓塞治疗：一项回顾性队列研究。

目的：研究检查点免疫疗法（CPI）和经动脉栓塞术（TAE）的先后顺序如何影响转移性黑色素瘤患者的总生存期（OS）：这项回顾性队列研究纳入了2011年9月至2022年1月期间同时接受TAE和CPI治疗的65例转移性黑色素瘤患者：栓塞前后接受 CPI 治疗的患者的 OS 明显更高（22 个月，95% CI 14-NR，p p p p 结论：栓塞前后接受 CPI 治疗的转移性黑色素瘤患者的 OS 明显更高：接受TAE的转移性黑色素瘤患者在栓塞前后接受CPI治疗的生存期更长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.